Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Controlled Clinical Trial
. 2007 Feb;34(2):185-96.
doi: 10.1007/s00259-006-0163-x. Epub 2006 Jul 11.

(11)C-acetate PET in the early evaluation of prostate cancer recurrence

Susanne Albrecht  1 , Franz Buchegger, Dmitri Soloviev, Habib Zaidi, Hansjoerg Vees, Haleem G Khan, Alain Keller, Angelika Bischof Delaloye, Osman Ratib, Raymond Miralbell
Affiliations
Controlled Clinical Trial

(11)C-acetate PET in the early evaluation of prostate cancer recurrence

Susanne Albrecht et al. Eur J Nucl Med Mol Imaging. 2007 Feb.

Abstract

Purpose: The first aim of the study was to investigate the diagnostic potential of (11)C-acetate PET in the early detection of prostate cancer recurrence. A second aim was the evaluation of early and late PET in this context.

Methods: The study population comprised 32 prostate cancer patients with early evidence of relapse after initial radiotherapy (group A) or radical surgery (group B). The median PSA of group A (n=17) patients was 6 ng/ml (range 2.6-30.2) while that of group B (n=15) was 0.4 ng/ml (range 0.08-4.8). Pelvic-abdominal-thoracic PET was started 2 min after injection of (11)C-acetate and evaluated after fusion with CT.

Results: Group A: Taking a SUV(max)> or =2 as the cut-off, PET showed local recurrences in 14/17 patients and two equivocal results. Distant disease was observed in six patients and an equivocal result was obtained in one. Endorectal MRI was positive in 12/12 patients. Biopsy confirmed local recurrence in six of six (100%) patients. PET was positive in five of the six patients with biopsy-proven recurrences, the result in the remaining patient being equivocal. Group B: Among the 15 patients, visual interpretation was positive for local recurrences in five patients and equivocal in four. One obturator lymph node was positive. Endorectal MRI was positive in 11/15 patients and equivocal in two. Positional correlation of positive/equivocal results on PET and endorectal MRI was observed in seven of nine patients. PSA decreased significantly after salvage radiotherapy in 8/14 patients, providing strong evidence for local recurrence. PET of the eight patients responding to RT was positive in three and equivocal in two.

Conclusion: (11)C-acetate PET was found to be valuable in the early evaluation of prostate cancer relapse. Optimising scanning time and use of modern PET-CT equipment might allow further improvement.

PubMed Disclaimer

Comment in

  • (11)C-acetate PET imaging in prostate cancer.
    Morris MJ, Scher HI. Morris MJ, et al. Eur J Nucl Med Mol Imaging. 2007 Feb;34(2):181-4. doi: 10.1007/s00259-006-0281-5. Eur J Nucl Med Mol Imaging. 2007. PMID: 17238014 No abstract available.

References

    1. Cancer Res. 2003 Sep 15;63(18):5838-43 - PubMed
    1. Mol Imaging Biol. 2006 Jan-Feb;8(1):43-8 - PubMed
    1. BJU Int. 2005 Apr;95(6):751-6 - PubMed
    1. Curr Opin Urol. 2005 May;15(3):181-6 - PubMed
    1. Radiology. 2005 May;235(2):623-8 - PubMed

Publication types